AstraZeneca

News

AstraZeneca spins out biotech to focus on autoimmune candida...

AstraZeneca’s biologics division MedImmune is to spin out a new standalone biotech to develop six early-stage inflammation and autoimmunity programmes.

News

Tesaro and Roche to combine drugs in bladder cancer trials

Tesaro is to combine its PARP-inhibitor drug Zejula with Roche’s PD-L1 immunotherapy Tecentriq in clinical trials for metastatic bladder cancer.

Partner Content

Partner Content

£500 special discount for Drug Discovery conference in 4 wee...

Drug Discovery Conference

News

AZ signs kidney drug deal with Ionis for up to $330m

Deal is result of six-year collaboration with AZ

News

Groundbreaking lung cancer approval a big boost for AZ's Imf...

AstraZeneca’s immunotherapy Imfinzi has gained US approval in an important new earlier treatment setting for lung cancer patients.

News

New tool will help pharma design better R&D apps

A not-for-profit organisation dedicated to encouraging life sciences R&D has launched a new tool to help companies in the sector design better apps and digital tools.

AstraZeneca spins out biotech to focus on autoimmune candida...

Tesaro and Roche to combine drugs in bladder cancer trials

£500 special discount for Drug Discovery conference in 4 wee...

AZ signs kidney drug deal with Ionis for up to $330m

Groundbreaking lung cancer approval a big boost for AZ's Imf...

New tool will help pharma design better R&D apps

Senju launches first-in-class dry eye disease drug in Japan

Using AI-driven synthetic personas to take your insights fur...

AstraZeneca

Editor's Picks